---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-004587"
form_type: "8-K"
ticker: "GTBP"
cik: "0000109657"
company_name: "GT Biopharma, Inc."
filed_at: "2024-02-01T23:59:59+00:00"
generated_at: "2026-06-06T10:38:57.429496+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# GT Biopharma announces 1-for-30 reverse stock split to regain Nasdaq compliance

## Summary
- Reverse split ratio 1:30 effective 5:00 PM ET Feb 2, 2024; post-split trading begins Feb 5.
- Outstanding shares reduced from ~41.4M to ~1.38M; authorized shares unchanged at 250M.
- No fractional shares issued; stockholders receive cash for fractional shares.
- Proportionate adjustments to outstanding stock options and equity awards.
- Action intended to regain Nasdaq $1.00 minimum bid price; ticker remains GTBP.

## SEC filing metadata
- accession: 0001493152-24-004587
- form_type: 8-K
- ticker: GTBP
- cik: 0000109657
- company_name: GT Biopharma, Inc.
- filed_at: 2024-02-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 3.03, 5.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/109657/000149315224004587/0001493152-24-004587-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/109657/000149315224004587/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-004587
- JSON: https://secwatch.observer/filing/0001493152-24-004587.json
- Plain text: https://secwatch.observer/filing/0001493152-24-004587.txt

## Key facts
- Governance Changes
  GT Biopharma, Inc.: Filed Certificate of Amendment to effect a 1-for-30 reverse stock split of common stock, effective February 2, 2024, with reduced outstanding shares and unchanged authorized shares (effective 2024-02-02).
  - Change: charter amendment
  - Effective: 2024-02-02
  source text: On February 1, 2024, GT Biopharma, Inc. filed a Certificate of Amendment of our Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect a reverse stock split of our common stock, par value $0.001 per share, at a ratio of 1-for-30.
  evidence_url: https://www.sec.gov/Archives/edgar/data/109657/000149315224004587/0001493152-24-004587-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.